Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and BEAM vs BEAM for Relapsed DLBCL (SPINOZA)
NCT02366663Phase 3Terminated
- Sponsor
- City of Hope
- Start
- Jan 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by City of Hope. Primary endpoint: Overall Survival at 5 years. Started Jan 2015; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02366663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366663.